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Abstract
Background: For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and
breast cancer (BC) risk is still unclear.
Methods: Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers
using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-
cohort retrospective analyses were performed.
Results: For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] ¼ 1.08,
95% confidence interval [CI]¼ 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by
26% (95% CI¼ 6% to 51%) and 39% (95% CI¼ 23% to 58%), respectively. For BRCA2mutation carriers, OCP use was associated with
BC risk in prospective analyses (HR¼ 1.75, 95% CI¼ 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated:
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HR¼ 1.06, 95% CI¼ 0.85 to 1.33; full cohort: HR¼ 1.52, 95% CI¼ 1.28 to 1.81). There was evidence of increasing risk with duration of
use, especially before the first full-term pregnancy (BRCA1: both retrospective analyses, P< .001 and P¼ .001, respectively; BRCA2:
full retrospective analysis, P¼ .002).
Conclusions: Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1
mutation carriers in young middle-aged women (40–50 years). For BRCA2mutation carriers, a causal association is also not
likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival
bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain
safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and non-
hormonal contraceptive methods should be discussed.
Women with germline mutations in BRCA1 and BRCA2 are at
substantially increased risk of breast and ovarian cancers (1).
The use of oral contraceptive preparations (OCPs) has been
found to be associated with reduced ovarian cancer risk for
both BRCA1 and BRCA2 mutation carriers (2–7). However, a key
issue in the clinical management of these mutation carriers is
whether or not use of OCPs is associated with breast cancer
(BC) risk. Prior findings are inconsistent and based on only a
few retrospective studies with the potential for recall, survival,
and testing biases. To evaluate the risk of BC associated with
use of OCPs for mutation carriers, we harmonized and com-
bined the data from three large international cohort consortia.
We analyzed the association between the use of OCPs and BC
risk in the first prospective analysis. For comparison with the
literature with a larger sample size, we also conducted left-
truncated and full cohort retrospective analyses in the same
cohort at younger ages.
Methods
Study Design and Study Participants
We harmonized and pooled information from three large
cohorts: the International BRCA1/2 Carrier Cohort Study
(IBCCS), the Kathleen Cuningham Foundation Consortium for
Research Into Familial Breast Cancer (kConFab) Follow-Up
Study, and the Breast Cancer Family Registry (BCFR). The
IBCCS/kConFab/BCFR collaboration combined 21 cohort studies
conducted in Western countries (1,8–11). Women were eligible
if they had a pathogenic mutation in either BRCA1 or BRCA2
and were between age 18 and 80 years at study enrollment.
Women were excluded if they had mutations in both genes or
were born before 1920, because their reproductive years pre-
ceded the availability of OCPs. The total eligible group, enrolled
in the prospective, retrospective, or both analyses, consisted of
6030 BRCA1 and 3809 BRCA2 mutation carriers.
Data Collection
Baseline and consecutive follow-up questionnaires elicited de-
tailed information on known or suspected risk factors for
breast and ovarian cancer. Data collection on OCP use included
ever use (no/yes), age at first or last use (years), and duration of
use (years); age sat first and last use for each period of use were
available for 75% of the women. Data on preventive surgeries
and cancer occurrence were collected from questionnaires,
from medical record validation, and from linkages to cancer
and/or pathology registries. Information on vital status was
obtained from municipal or death registries or from contact
persons in the family.
Statistical Analysis
To estimate hazard ratios (HRs), time-dependent Cox propor-
tional hazards regression models were used, with age as the
time scale, and stratified by birth cohort and study. The propor-
tional hazard assumption was not violated when comparing
log-minus-log and hazard curves with each other. The effect of
familial clustering on estimates of precision was accounted for
using robust variance estimation. All tests of statistical signifi-
cance were two-sided. Associations by birth cohort, attained
age (35 years, >35 years), and study were also assessed.
Hazard ratios were estimated for both prospective and retro-
spective (left-truncated and full-cohort) models in the same
study population to enable a comparison with the literature,
and to investigate potential biases and age-specific differences.
For prospective analyses, OCP data from baseline and follow-up
questionnaires were combined and imputed for the interval be-
tween age at last questionnaire and age at linkage with cancer
registries. For retrospective analyses, only data from the base-
line questionnaire were used. Characteristics of OCP use that
were identified a priori for investigation included ever use of
OCPs (use for more than six months), recency of use (time since
last use, in years), age at first use (years), calendar year at first
use (<1975, 1975, proxy for changes in OCP formulations; spe-
cific formulations unknown), total duration of use (years), and
duration of use before first full-term pregnancy (FFTP); they
were time-dependently included in the model, for each year of
observation. Potential confounders were family history, defined as
the number of first- or second-degree relatives diagnosed with BC
(none, 1, 2), parity (no/yes, time-dependent), age at FFTP (time-
dependent), breast feeding (never/ever and duration in years,
time-dependent), and risk-reducing salpingo-oophorectomy
(RRSO; no/yes and “no or <3 years since RRSO”/“yes, 3 years
since RRSO”; time-dependent). None of these variables changed
the hazard ratio for OCP exposure and BC risk by more than 10%,
and therefore they were not included in the final analyses.
All statistical tests were two-sided, a P value of less than .05
was considered statistically significant. The analyses were per-
formed using STATA-13.0 (Statcorp, College Station,TX).
Prospective Cohort Analysis
Prospective follow-up started at baseline cohort recruitment
or mutation testing, whichever came last, to standardize the
potential influence of being aware of the mutation on use of
OCPs during follow-up. If age at mutation testing was un-
known (1%) or if women were tested in a research setting
and it was unknown whether they opted for a clinical test
(6%), follow-up started at baseline questionnaire completion.
At start of follow-up, women had no history of cancer (exclu-
sive nonmelanoma skin cancer) and had not undergone a
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bilateral risk-reducing mastectomy (RRM). Person-years were
censored at age of diagnosis of first primary BC (invasive or in
situ), diagnosis of another cancer, RRM, death, last follow-up, or
age 80 years, whichever came first. Last follow-up was defined
as last questionnaire, contact, or linkage, whichever came last.
Retrospective Cohort Analysis
Two retrospective analyses were conducted. In “full-cohort” ret-
rospective analyses, follow-up commenced at birth. The “left-
truncated” retrospective analysis started follow-up five years
preceding the date of the baseline questionnaire to reduce the
possibility of survival bias. At the start of follow-up, carriers
were included in this left-truncated analysis only if they had
not been diagnosed with cancer (exclusive nonmelanoma skin
cancer) or undergone RRM. In both retrospective analyses, person-
years were censored at age of diagnosis of the first primary BC (in-
vasive or in situ), diagnosis of another cancer, RRM, mutation test,
or baseline questionnaire, whichever came first. By taking age at
mutation testing into account, all women were unaware of carry-
ing the mutation during retrospective person-years. To account
for the oversampling of affected individuals, a weighted cohort ap-
proach was used, as described by Antoniou et al. (12).
Details on study design, study participants, data collection,
and statistical analyses can be found in the Supplementary
Methods (available online).
Results
BRCA1 Mutation Carriers
The prospective cohort comprised 2276 women, of whom 269
(11.8%) were diagnosed with incident BC during follow-up. The
left-truncated retrospective and full-cohort retrospective analy-
ses included 3828 women (1095, 28.6%, with BC) and 5705
women (2525, 44.3%, with BC), respectively (Table 1). The pro-
portion of young women (<35 years) with BC was lowest in the
prospective cohort (14.1% vs 27.9% and 29.7%, respectively). In
total, 83% of all women in the prospective cohort and 73% and
75% of women in the retrospective cohorts had ever used OCPs
by the end of follow-up (Table 2).
From the prospective cohort analysis, ever OCP use was not
associated with BC risk (HR ¼ 1.08, 95% confidence interval [CI]
¼ 0.75 to 1.56). Hazard ratios did not vary according to total du-
ration of use, age at first use, recency of use, or duration of use
before FFTP (Table 2). In contrast, from the left-truncated and
full-cohort retrospective analyses, we found an association be-
tween ever OCP use and BC risk (HR ¼ 1.26, 95% CI ¼ 1.06 to 1.51,
and HR ¼ 1.39, 95% CI ¼ 1.23 to 1.58, respectively). Risk increased
with longer lifetime duration of use (eg, left-truncated; use < 5
years: HR ¼ 1.28; 5–9 years: HR ¼ 1.27; 10 years: HR ¼ 1.37;
Ptrend ¼ .01) and longer duration of use preceding FFTP (eg, left-
truncated; <5 years: HR ¼ 1.05; 5–9 years: HR ¼ 1.15; 10 years:
HR ¼ 1.41; Ptrend ¼ .001). From the full-cohort retrospective anal-
ysis, but not from the left-truncated analysis, there was an in-
creased risk of BC with younger age at first OCP use (Ptrend <
.001) and longer duration of use after FFTP (Ptrend ¼ .02).
The hazard ratios for associations between ever OCP use and
BC risk did not vary by birth cohort or study in either the left-
truncated analysis or the full-cohort retrospective analysis. The
numbers in birth cohort and study strata were too low to draw
conclusions from the prospective analysis (data not shown).
Additional results were restricted to the left-truncated retro-
spective and prospective analyses as they are susceptible to
fewer biases. When stratified by attained age (35, >35 years)
(Table 3), the left-truncated retrospective analysis suggested
that the positive trend with longer duration of use before
FFTP was restricted to younger women (35 years; <5 years: HR
¼ 1.19; 5–9 years: HR ¼ 1.37; 10 years: HR ¼ 1.88; >35 years; <5
years: HR ¼ 1.10; 5–9 years: HR ¼ 1.12; 10 years: HR ¼ 1.18;
Pdifference ¼ .08). The sample size was too small to carry out a
stratified analysis using the prospective data, with only two to
11 BC cases per category.
To try to explain the different findings from the prospective
and left-truncated retrospective analyses, we performed explor-
atory analyses of time since last OCP use before FFTP. From the
left-truncated retrospective analysis, BC risk decreased with a
longer time since “last OCP use before FFTP” (Ptrend ¼ .02)
(Figure 1). Although the magnitude of the hazard ratios was
smaller from the prospective analysis, the hazard ratios fol-
lowed a similar pattern.
BRCA2 Mutation Carriers
The prospective, left-truncated retrospective, and full retrospec-
tive cohorts comprised 1610 women (157, 9.8%, with incident BC
diagnosed during follow-up), 2512 women (752, 29.9%, with BC),
and 3521 women (1548, 44.0%, with BC), respectively (Table 4).
As for BRCA1 mutation carriers, for BRCA2 mutation carriers,
the proportion of young women (<35 years) with BC was lowest
in the prospective cohort (8.2% vs 16.1% and 16.4%,
respectively).
In total, 83%, 75%, and 72% of all women from the prospec-
tive, left-truncated, and full retrospective cohorts, respectively,
had ever used OCPs by the end of follow-up (Table 5).
We found a positive association between ever OCP use and BC
risk from both the prospective and full-cohort retrospective analy-
ses (HR ¼ 1.75, 95% CI ¼ 1.03 to 2.97, and HR ¼ 1.52, 95% CI ¼ 1.28
to 1.81, respectively) but not from the left-truncated analysis (HR
¼ 1.06, 95% CI ¼ 0.85 to 1.33). From the full-cohort retrospective
analysis, BC risk was higher for women with younger age at first
use (17 years: HR ¼ 1.53; 18–22 years: HR ¼ 1.66; 23 years: HR ¼
1.40; Ptrend ¼ .02) and longer duration of use (<5 years: HR ¼ 1.46;
5–9 years: HR ¼ 1.68; 10 years: HR ¼ 1.70; Ptrend < .001), most
clearly for use before FFTP (<5 years: HR ¼ 1.30; 5–9 years: HR ¼
1.38; 10 years: HR ¼ 1.64; Ptrend ¼ .002). There was no evidence of
variation in the hazard ratios by any of these characteristics from
the prospective or left-truncated analyses.
The association between ever OCP use and BC risk did not
vary by birth cohort or study from the retrospective analyses
(data not shown; the numbers were too low in the prospective
cohort to perform these analyses). The results from the strati-
fied analyses by age were consistent with the unstratified retro-
spective analyses (left-truncated; all ages: HR ¼ 1.06; 35 years:
HR ¼ 1.01; >35 years: HR ¼ 1.03). For BRCA2 mutation carriers,
we repeated the exploratory analysis by time since last OCP use
before FFTP that we conducted for BRCA1 mutation carriers, but
no evidence for an association was found (data not shown).
Discussion
For BRCA1 mutation carriers, no association between ever OCP
use and BC risk was found from the prospective analysis. From
the left-truncated retrospective analysis, however, we found a
positive association (HR ¼ 1.26), which was stronger without
L. H. Schrijver et al. | 3
left-truncation (full cohort: HR ¼ 1.39). Longer duration of use,
especially before FFTP, was associated with an increasing risk of
BC from both retrospective analyses, but not from the prospec-
tive analysis. The increasing risk associated with a younger age
at first use found from the full-cohort retrospective analysis
was not observed in the left-truncated retrospective or prospec-
tive analyses. For BRCA2 mutation carriers, we found positive
associations between ever OCP use and BC risk from both the
prospective and full-cohort retrospective analyses (HR ¼ 1.75
and HR ¼ 1.52, respectively). However, there was no increased
risk after left-truncation (HR ¼ 1.06). From full-cohort retrospec-
tive analyses, increasing risks with younger age at first use and
longer durations of use, especially before FFTP, were found, but
these trends again did not persist in left-truncated retrospective
or prospective analyses. It is important to note, however, that
for both BRCA1 and BRCA2 mutation carriers, the confidence
Table 1. Characteristics of BRCA1 mutation carrier cohort, by study design
Prospective
(n ¼ 2276)
Retrospective “left-truncated”
(n ¼ 3828)
Retrospective “full-cohort”
(n ¼ 5705)
BRCA1 BCþ BC- BCþ BC- BCþ BC-
No. (%) 269 (11.8) 2007 (88.2) 1095 (28.6) 2733 (71.4) 2525 (44.3) 3180 (55.7)
Mean age at start of FUP (SD), y 40.7 (10.3) 37.5 (11.8) 38 (9.4) 34.1 (11.8) Birth Birth
Mean age at end of FUP (SD), y 44.9 (10.3) 43.1 (12.2) 41 (9.3) 38.4 (11.6) 40.1 (8.8) 38.7 (11.6)
Age at end of FUP, No. (%)
<35 y 38 (14.1) 560 (27.9) 305 (27.9) 1111 (40.7) 750 (29.7) 1237 (38.9)
35–64 y 216 (80.3) 1327 (66.2) 770 (70.3) 1555 (56.9) 1746 (69.2) 1869 (58.7)
65þ y 15 (5.6) 120 (6.0) 20 (1.8) 67 (2.5) 29 (1.2) 74 (2.3)
Mean years of FUP (SD), y 4.2 (3.3) 5.6 (3.7) 3.0 (1.3) 4.3 (1.1) 40.1 (8.8) 38.7 (11.6)
Censored for, No. (%)
Breast cancer 269 (100.0) — 1095 (100.0) — 2525 (100.0) —
Ovarian cancer* — 49 (2.4) — 240 (8.8) — 413 (13.0)
Other cancer* — 45 (2.2) — 34 (1.2) — 145 (4.6)
Bilateral RRM*,† — 301 (15.0) — 201 (7.4) — 252 (7.9)
Death* — 5 (0.3) — 0 (0.0) — 0 (0.0)
Maximum FUP* — 1607 (80.1) — 2258 (86.6) — 2370 (74.5)
Year at end of FUP, No. (%)
1959–1989 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 573 (22.7) 114 (3.6)
1990–2000 26 (9.7) 32 (1.6) 558 (51.0) 902 (33.0) 1327 (52.6) 1150 (36.2)
2001–2012 243 (90.3) 1975 (98.4) 537 (49.0) 1831 (67.0) 625 (24.8) 1916 (60.3)
Birth year, No. (%)
1920–1959 111 (41.3) 552 (27.5) 508 (46.4) 886 (32.4) 1637 (64.8) 1181 (37.1)
1960–1970 114 (42.4) 640 (31.9) 422 (38.5) 916 (33.5) 699 (27.7) 1026 (32.3)
1971–1992 44 (16.4) 815 (40.6) 165 (15.1) 931 (34.1) 189 (7.5) 973 (30.6)
Study, No. (%)
1. EMBRACE‡ 41 (8.7) 432 (91.3) 309 (30.4) 707 (69.6) 740 (47.4) 820 (52.6)
2. GENEPSO‡ 46 (9.4) 442 (90.6) 136 (17.3) 649 (82.7) 325 (32.0) 691 (68.0)
3. HEBON‡ 40 (16.5) 202 (83.5) 84 (21.1) 314 (78.9) 330 (41.2) 472 (58.9)
4. kConFab 55 (16.9) 270 (83.1) — — — —
5. BCFR 50 (15.3) 277 (84.7) 257 (39.4) 396 (60.6) 456 (51.4) 432 (48.7)
6. Other‡,§ 37 (8.8) 384 (91.2) 309 (31.7) 667 (68.3) 674 (46.8) 765 (53.2)
RRSO, No. (%)
No 153 (56.9) 1284 (64.0) 1059 (96.7) 2601 (95.2) 2465 (97.6) 3041 (95.6)
Yes 116 (43.1) 723 (36.0) 36 (3.3) 132 (4.8) 60 (2.4) 139 (4.4)
No. of breast cancers among 1st- and
2nd-degree relatives, No. (%)
No BC 54 (20.1) 546 (27.2) 259 (23.7) 678 (24.8) 593 (23.5) 817 (25.7)
1 91 (33.8) 628 (31.3) 317 (29.0) 763 (27.9) 679 (26.9) 888 (27.9)
2 108 (40.2) 629 (31.3) 288 (26.3) 872 (31.9) 669 (26.5) 961 (30.2)
Missing 13 (4.8) 192 (9.6) 190 (17.4) 398 (14.6) 524 (20.8) 489 (15.4)
Cancer type unknown 3 (1.1) 12 (0.6) 41 (3.7) 22 (0.8) 60 (2.4) 25 (0.8)
Parity, No. (%)
Nulliparous 51 (19.0) 602 (30.0) 250 (22.8) 914 (33.4) 513 (20.3) 1020 (32.1)
Parous 208 (77.3) 1405 (70.0) 845 (77.2) 1819 (66.6) 2012 (79.7) 2160 (67.9)
Missing 10 (3.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
*After exclusion of women in the preceding categories. BC ¼ breast cancer; FUP ¼ follow-up; RRM ¼ risk-reducing mastectomy.
†RRM occurring at the same age or within one year of BC diagnosis was ignored.
‡IBCCS is a collaboration of 1) EMBRACE, 2) GENEPSO, 3) HEBON, and 6) other.
§“Other” included the following studies: MUV, MODSQUAD, GC-HBOC, Lund-BRCA, OUH, NIO, IHCC, HCSC, Stockholm-BRCA, INHERIT, CNIO, Milan Italy, HSP, DKFZ,
Dusseldorf Germany, Belgium (order is based on number of carriers included in the analyses).
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intervals of the estimates from the retrospective and prospec-
tive analyses overlapped.
All studies on OCP use and risk of BC for BRCA1/2 mutation
carriers to date have performed full-cohort retrospective analy-
ses (6,13–17). Among “independent” studies, using data not in-
cluded in the present study, most found a statistical
significantly increased association with BC risk for BRCA1 muta-
tion carriers, comparable with our full-cohort retrospective
analysis (13,17,18). In addition, Kotsopoulos et al. and Ursin et
al. also found that the increased risk was limited to early-onset
BC (<40 years) (17,18). For BRCA2 mutation carriers, results from
two previous independent full-cohort analyses were very incon-
sistent (odds ratio ¼ 0.94 vs HR¼ 2.07). However, in our study, the
magnitude of the associations estimated from the full-cohort
analysis became weaker (BRCA1) or even disappeared (BRCA2)
when survivors of more than five years were excluded (left-trun-
cated retrospective analyses). This might suggest the presence of
survival bias, driven by a lower stage at diagnosis for OCP users
compared with nonusers, as found for the general population (19).
However, a true age-related effect that disappears when the co-
hort gets older might be another explanation. Apart from survival
bias, there was evidence for testing bias, resulting from the non-
random uptake of genetic testing. We adjusted for the oversam-
pling of carriers with BC by using the weighted cohort approach
(12). Furthermore, the presence of recall and response biases can-
not be excluded in the retrospective analyses.
We consider the findings from prospective analyses to be our
main results, as they are free of testing bias and hardly influenced
by recall and survival bias. They showed no association between
the various characteristics of OCP use and BC risk for BRCA1muta-
tion carriers, whereas compared with never users, ever OCP users
had a higher risk of BC for BRCA2 mutation carriers. However,
trends with duration, starting age, or recency of OCP use were ab-
sent. Such trends might have been expected if the association had
been causal, but power was limited to detect such trends. Results
of our adequately powered next-best left-truncated analyses sup-
port the absence of an association between OCP use and risk of BC
for BRCA2mutation carriers.
Although prospective results showed no associations for
BRCA1 mutation carriers, weak associations between OCP use and
BC risk arose in left-truncated analyses. This seemed to be driven
by duration of use before FFTP. Exploratory analyses showed that
duration of OCP use before FFTP was associated with BC risk diag-
nosed before age 35 years), consistent with findings of Pike et al.
in the general population (20). The prospective cohort included a
much smaller proportion of such young BC cases (35 years 14.1%
vs 27.9%, respectively) (Table 1). Additionally, the positive associa-
tion of OCP use before FFTP with risk of early-onset BC seemed to
diminish with time since last use before FFTP. Thus, the prospec-
tive cohort may have been too old to detect the temporal effect of
OCP use before FFTP on risk of early-onset BC.
We did not consider a combined BRCA1/2 mutation carrier
analysis to increase prospective power, because of our own gene-
specific findings and those of studies that reported different asso-
ciations for BRCA1 and BRCA2 mutation carriers (21–23). Such dif-
ferences may be caused by differences in BC subtype, being more
often ER-negative in BRCA1-associated BC and ER-positive in
BRCA2-associated BC in youngmiddle-aged women (24).
This is the first prospective study to investigate the associa-
tion between OCP use and BC risk for BRCA1 and BRCA2 muta-
tion carriers. Two previous reports were based on left-truncated
retrospective analyses; however, these form a subset of current
retrospective analysis. Brohet et al. (IBCCS) found a hazard ratio
of 1.48 (95% CI ¼ 0.92 to 2.36) for ever OCP use in 967 BRCA1/2Ta
b
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mutation carriers combined (14). Haile et al. (BCFR and kConFab),
restricting analyses to women younger than age 50 years, found a
hazard ratio of 0.77 (95% CI ¼ 0.53 to 1.12) for ever OCP use in 497
BRCA1 mutation carriers and a hazard ratio of 1.62 (95% CI ¼ 0.90
to 1.92) for 307 BRCA2 mutation carriers (16). Results by Haile et al.
were inconsistent with our findings in mutation carriers younger
than age 50 years (BRCA1: HR ¼ 1.32, 95% CI ¼ 1.10 to 1.58; BRCA2:
HR¼ 1.08, 95% CI¼ 0.86 to 1.36), and additionally, there was no ev-
idence for heterogeneity between the harmonized studies in our
cohort (BRCA1: P ¼ .683; BRCA2: P¼ .882).
The association of OCP use with BC risk is not the only con-
sideration in the clinical OCP management of BRCA1 and BRCA2
Table 3. Breast cancer HR estimates for BRCA1mutation carriers stratified by attained age, the left-truncated retrospective cohort
Retrospective “left-truncated”
BCþ BC-
HR (95% CI) †
BCþ BC-
No. (%)* No. (%)* No. (%)* No. (%)* HR (95% CI)†
35 y (n ¼ 1955) >35 y (n ¼ 2255)
OCP use
Never (<6 mo) 40 (11.1) 249 (15.6) 1.00 165 (22.4) 363 (23.9) 1.00
Ever 302 (84.1) 1283 (80.4) 1.41 (1.01 to 1.97) 546 (74.2) 1062 (69.9) 1.19 (0.99 to 1.44)
Ever, starting age Unknown 6 (1.7) 45 (2.8) 14 (1.9) 63 (4.2)
Missing 11 (3.1) 19 (1.2) 11 (1.5) 31 (2.0)
Duration by FFTP‡
Before FFTP, y
Never (<6 mo) 57 (15.9) 312 (19.6) 1.00 260 (35.3) 553 (36.4) 1.00
<5 39 (10.9) 284 (17.8) 1.19 (0.77 to 1.84)§ 105 (14.3) 240 (15.8) 1.10 (0.86 to 1.40)§
5–9.99 78 (21.7) 426 (26.7) 1.37 (0.93 to 2.02)k 116 (15.8) 249 (16.4) 1.12 (0.87 to 1.45)k
10 81 (22.6) 255 (16.0) 1.88 (1.27 to 2.79)¶ 74 (10.1) 157 (10.3) 1.18 (0.87 to 1.60)¶
Ptrend per year .001# .08 #
After FFTP, y
Never (<6 mo) 178 (49.6) 962 (60.3) 1.00 336 (45.7) 715 (47.1) 1.00
<5 41 (11.4) 176 (11.0) 1.03 (0.70 to 1.50) 95 (12.9) 189 (12.4) 1.10 (0.86 to 1.40)
5–9.99 24 (6.7) 101 (6.3) 1.09 (0.68 to 1.76) 60 (8.2) 129 (8.5) 1.01 (0.76 to 1.36)
10 12 (3.3) 38 (2.4) 1.93 (0.99 to 3.75) 64 (8.7) 166 (10.9) 0.89 (0.67 to 1.18)
Ptrend per year .4 .86
Ever, no period-specific data 93 (25.9) 300 (18.8) 170 (23.1) 289 (19.0)
OCP or FFTP data missing 11 (3.1) 19 (1.2) 11 (1.5) 31 (2.0)
BC ¼ breast cancer; CI ¼ confidence interval; FFTP ¼ first full-term pregnancy; HR ¼ hazard ratio; OCP ¼ oral contraceptive preparations.
*Distribution of variables at end of follow-up..
†Intrinsically stratified on study (EMBRACE, GENEPSO, HEBON, BCFR, other) and birth cohort (1920–1952, 1953–1964, 1965–1992). Clustered on family membership.
‡Duration before FFTP and after FFTP were included in one multivariable model. Nulliparous women only contributed to various duration categories before FFTP and
were placed in the category “never user” after FFTP. Adjusted for age at FFTP (nulliparous, 20, 21–25, >25 years)
§Test for difference: P ¼ .406.
kTest for difference: P ¼ .757.
¶Test for difference: P ¼ .055.
#Test for difference: P ¼ .077.
Figure 1. Association between time since last oral contraceptive preparation use before first full-term pregnancy and breast cancer risk among BRCA1 mutation car-
riers. Black dot indicates retrospective “left-truncated” analysis. Black square indicates prospective analysis. Nonfilled symbols are 95% confidence intervals. *Adjusted
for oral contraceptive preparation use after first full-term pregnancy. FFTP ¼ first full-term pregnancy; OCP ¼ oral contraceptive preparation.
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mutation carriers, because these mutations are also associated
with high risk of ovarian cancer (1). The meta-analysis by
Moorman et al. reported a consistent inverse association for
OCP use and risk of ovarian cancer, proportional with duration
of use (25), although potential bias was not investigated. The
relative risk reduction appears to be comparable to that in the
general population, so that the absolute ovarian cancer risk re-
duction is large. However, in many Western countries, the ma-
jority of BRCA1 and BRCA2 mutation carriers (70%–75%) now opt
for RRSO between age 35 and 50 years, when childbearing is
completed (26,27), whereas the uptake of RRM is lower (35%–
44%) (28) and varies widely between countries. These aspects
should be taken into consideration when balancing the risks
and benefits of OCP use for BRCA1 and BRCA2 mutation
carriers.
In conclusion, prospective analyses did not show that past
use of OCP causes an increased BC risk for BRCA1 mutation car-
riers in young middle-aged women (40–50 years). For BRCA2
Table 4. Characteristics of BRCA2 mutation carrier cohort, by study design
Prospective
(n ¼ 1610)
Retrospective “left-truncated”
(n ¼ 2512)
Retrospective “full-cohort”
(n ¼ 3521)
BRCA2 BCþ BC- BCþ BC- BCþ BC-
No. (%) 157 (9.8) 1453 (90.3) 752 (29.9) 1760 (70.6) 1548 (44.0) 1973 (56.0)
Mean age at start of FUP (SD), y 45.1 (10.1) 40 (12.6) 40.9 (9.6) 36.4 (12.5) Birth Birth
Mean age at end of FUP (SD), y 49 (10.3) 45.1 (13.0) 44 (9.5) 40.8 (12.3) 43.4 (9.1) 41 (12.4)
Age at end of FUP, No. (%)
<35 y 13 (8.2) 337 (23.2) 121 (16.1) 593 (33.7) 254 (16.4) 652 (33.1)
35–64 y 132 (84.1) 993 (68.4) 611 (81.3) 1092 (62.0) 1261 (81.4) 1232 (62.5)
65þ y 12 (7.6) 123 (8.5) 20 (2.7) 75 (4.3) 33 (2.1) 89 (4.5)
Mean years of FUP (SD) 3.8 (3.1) 5 (3.4) 3 (1.2) 4.5 (1.0) 43.4 (9.1) 41 (12.4)
Censored for, No. (%)
Breast cancer 157 (100.0) — 752 (100.0) — 1548 (100.0) —
Ovarian cancer* — 9 (0.6) — 85 (4.8) — 142 (7.2)
Other cancer* — 29 (2.0) — 36 (2.1) — 140 (7.1)
Bilateral RRM*,† — 182 (12.5) — 117 (6.7) — 132 (6.7)
Death† — 8 (0.6) — 2 (0.1) — 2 (0.1)
Maximum FUP* — 1225 (84.3) — 1520 (86.4) — 1557 (78.9)
Year at end of FUP, No. (%)
1959–1989 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 267 (17.3) 70 (3.6)
1990–2000 15 (9.6) 12 (0.8) 335 (44.6) 320 (18.2) 767 (49.6) 433 (22.0)
2001–2012 142 (90.5) 1441 (99.2) 417 (55.5) 1440 (81.8) 514 (33.2) 1470 (74.5)
Birth year, No. (%)
1920–1959 86 (54.8) 459 (31.6) 406 (54.0) 612 (34.8) 1067 (68.9) 776 (39.3)
1960–1970 60 (38.2) 481 (33.1) 281 (37.4) 598 (34.0) 401 (25.9) 630 (31.9)
1971–1992 11 (7.0) 513 (35.3) 65 (8.6) 550 (31.3) 80 (5.2) 567 (28.7)
Study, No. (%)
1. EMBRACE‡ 42 (8.7) 441 (91.3) 269 (28.9) 662 (71.1) 611 (45.1) 744 (54.9)
2. GENEPSO‡ 18 (5.5) 307 (94.5) 71 (14.6) 416 (85.4) 161 (26.9) 437 (73.1)
3. HEBON‡ 4 (5.3) 71 (94.7) 26 (20.3) 102 (79.7) 90 (38.0) 147 (62)
4. kConFab 38 (13.2) 250 (86.8) — — — —
5. BCFR 33 (12.9) 222 (87.1) 226 (43.5) 294 (56.5) 356 (52.6) 321 (47.4)
6. Other‡,§ 22 (12.0) 162 (88.0) 160 (35.9) 286 (64.1) 330 (50.5) 324 (49.5)
RRSO, No. (%)
No 106 (67.5) 1007 (69.3) 725 (96.4) 1689 (96.0) 1494 (96.5) 1897 (96.2)
Yes 51 (32.5) 446 (30.7) 27 (3.6) 71 (4.0) 54 (3.5) 76 (3.9)
No. of breast cancers among 1st- and 2nd-degree relatives, No. (%)
No BC 17 (10.8) 285 (19.6) 131 (17.4) 292 (16.6) 276 (17.8) 347 (17.6)
1 49 (31.2) 446 (30.7) 231 (30.7) 452 (25.7) 422 (27.3) 489 (25.2)
2 78 (49.7) 556 (38.3) 209 (27.8) 715 (40.6) 446 (28.8) 756 (38.3)
Missing 13 (8.3) 153 (10.5) 143 (19.0) 292 (16.6) 350 (22.6) 361 (18.3)
Cancer type unknown 0 (0.0) 13 (0.9) 38 (5.1) 9 (0.5) 54 (3.5) 11 (0.6)
Parity, No. (%)
Nulliparous 22 (14.0) 406 (27.9) 142 (18.9) 525 (29.8) 274 (17.7) 572 (29.0)
Parous 127 (80.9) 1047 (72.1) 610 (81.1) 1235 (70.2) 1274 (82.3) 1401 (71.0)
Missing 8 (5.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
BC ¼ breast cancer; FUP ¼ follow-up; RRM ¼ risk-reducing mastectomy.
*After exclusion of women in the preceding categories.
†RRM occurring at the same age or within one year of BC diagnosis was ignored.
‡IBCCS is a collaboration of 1) EMBRACE, 2) GENEPSO, 3) HEBON, and 6) Other.
§“Other” included the following studies: GC-HBOC, MUV, MODSQUAD, INHERIT, HCSC, OUH, Lund-BRCA, CNIO, NIO, Stockholm-BRCA, Milan Italy, HSP (order is based
on number of carriers included in the analyses).
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mutation carriers, a causal association is also not likely at those
ages, but power was limited. For both BRCA1 and BRCA2 muta-
tion carriers, prospective analyses do not support retrospective
findings that BC risk is increased after long-term duration of
use, especially before FFTP. These retrospective results were
consistent between full-cohort and left-truncated analyses for
BRCA1 mutation carriers, but not for BRCA2 mutation carriers.
Inconsistent prospective and retrospective findings could be
due to survival bias or a true association for younger women,
who were under-represented in the prospective cohort.
Therefore, despite this analysis of a large number of carriers
with a prospective component, there remains uncertainty about
the impact of OCP use on BC risk in carriers, and this uncer-
tainty should be discussed with each individual woman to help
her make a personalized decision about OCP use that takes into
account her personal circumstances and values. Given the un-
certain safety of long-term OCP use for BRCA1/2 mutation car-
riers, OCP use for indications other than contraception should
be avoided and nonhormonal contraceptive methods (eg, cop-
per intrauterine device) should be discussed.
Further extension and follow-up of these cohorts will provide
more precise risk estimates and hence more clarity in the advice
that can be provided to BRCA1 and BRCA2mutation carriers.
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